Table 2.
Clinical characteristics of participants overlapping between microbiome and metabolomics cohorts
| Characteristics | ALS group (n = 54) | Control group (n = 79) | P-value |
|---|---|---|---|
| Age, yearsa | 66.7 ± 9.4 (43.1–84.8) | 61.2 ± 8.3 (38.8–86.3) | 0.004b |
| Sex | – | – | |
| Male | 33 (61.1%) | 30 (38.0%) | 0.013c |
| Female | 21 (38.9%) | 49 (62.0%) | |
| Family history of ALS | – | – | |
| Yes | 6 (11.1%) | 0 (0%) | |
| No | 47 (87.0%) | 79 (100.0%) | |
| Unknown | 1 (1.9%) | 0 (0%) | |
| Race | – | – | |
| White | 54 (100.0%) | 79 (100.0%) | |
| ALS with frontotemporal dementia | 0 (0%) | – | |
| Onset segment | – | – | |
| Bulbar | 17 (31.5%) | – | |
| Cervical | 19 (35.2%) | – | |
| Lumbar | 17 (31.5%) | – | |
| Respiratory | 1 (1.9%) | – | |
| El Escorial criteria | – | – | |
| Definite | 7 (13.0%) | – | |
| Probable | 23 (42.6%) | – | |
| Probable, lab supported | 13 (24.1%) | – | |
| Possible | 8 (14.8%) | – | |
| Suspected | 3 (5.6%) | – | |
| ALS Functional Rating Scale-Revisedd | 38.0 (34.0–40.8) | – | |
| Days from symptom onset to diagnosisd | 370.5 (231.8–588.5) | – | |
| Feeding tube | – | – | |
| Yes | 4 (7.4%) | – | |
| No | 50 (92.6%) | – | |
| Days from diagnosis to stool sampled | 82.5 (44.0–193.2) | – |
Bold font indicates significant P-values.ALS = amyotrophic lateral sclerosis.
aMean ± standard deviation (range).
bStudent’s t-test.
cFisher’s exact test.
dMedian (interquartile range).